Zika vaccines have been developed for vaccination and prevention against diseases caused by the zika virus, which belongs to the genus Flavivirus and is transmitted by Aedes mosquitoes. It can be also transmitted through blood transfusion, sexual contact, or infected pregnant women to the fetus. In 2016, the World Health Organization announced that the zika virus no longer constitutes a public health emergency of international concern because the major causes of the virus were asymptomatic. As of January 2020, there are no areas with a current Zika outbreak.
However, Zika is still a problem in many parts of the world. Thus, travelers should take steps to prevent getting the virus during travel, as well as to prevent spreading it when they return home, as there is no medicine or vaccine for Zika. The Zika virus has been spreading to parts of the world ever since it was discovered. Until now, several clinical trials have been conducted on Zika vaccines to prevent the disease. As of April 2019, no Zika vaccines have been approved for clinical use, although there are currently several vaccines in clinical trials.
The goal of the Zika vaccines is to produce specific antibodies against the Zika virus to prevent infection and critical illness. Currently, no vaccine or prophylactic treatment is available for the prevention of the virus, but there are medications and treatments available to help reduce the discomfort associated with the disease. However, there are different types of vaccines that may protect against the Zika virus, such as genetically engineered vaccines, mRNA vaccines, purified inactivated vaccines, live attenuated vaccines, viral vector-based vaccines, and DNA-based vaccines.
Zika outbreaks have been reported in the Pacific region, South/Central America, the Caribbean, Africa, and parts of south and Southeast Asia. According to the Centers for Disease Control and Prevention (CDC), in 2018 and 2019, there have been no reports of Zika virus transmission by mosquitoes in the continental United States.
Latest released the research study on Zika Virus Vaccines Market, offers a detailed overview of the factors influencing the global business scope.
Download Free Sample Report @ https://dpiresearch.com/request-a-free-sample-reportZika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue, and yellow fever.
Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopmental disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth.
The WHO is predicting up to 4 Million Zika cases in the Americas by 2016 and the World Bank is projecting the short-term economic impact for 2016, in Latin America and the Caribbean to be about US$3.5 Billion.With fears of Zika virus reaching new heights, Zika virus vaccines are gaining popularity.
Key trends in terms of partnerships, collaborations, and licensing agreements are analyzed with details.The report concludes with the profiles of major players in the Zika virus vaccines development such as Sanofi Pasteur, ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt.
The major players are evaluated on various parameters such as company overview, product outlook, and Zika virus vaccines latest development and trends.This 87 Page report has been analyzed from 7 viewpoints:Zika Virus – Introduction, Signs, and Symptoms, Transmission, Diagnosis, Treatment & PreventionCurrent Situation & Areas with Zika VirusCompetitive Landscape of The Zika Virus Vaccines CompaniesFunding in Zika Virus Vaccines ResearchZika Virus Vaccines – Clinical Trials Insight by Phase & Trial StatusZika Virus Vaccines – Regulatory LandscapeKey Companies AnalysisFor More Information@ https://dpiresearch.com/reports/zika-virus-vaccines-market/The report is readily available and can be dispatched immediately after payment confirmation.Would like to place an order or any question, please feel free to contact at [email protected] of the Report:DPI Research provides customization of the report as per your need.
The global was valued at 1509.98 Million USD in 2021 and will grow with a CAGR of 2.82% from 2021 to 2027A Zika Vaccine is intended to stop the symptoms and complications of Zika viral infection in humans.
As Zika viral infection of pregnant girls might lead to innate defects within the newborn, the immunogen can plan to defend against innate Zika syndrome throughout the present or any future happening.The "Global Zika Vaccines market research for 2027" may be a skilled and in-depth study of the business with a special target international market analytic thinking.
the world market is anticipated to witness high growth over the forecast amount.
what is more, it sheds lightweight on the excellent competitive landscape of the world market.
The report additional offers a dashboard summary of leading corporations encompassing their prospering selling ways, market contribution, recent developments in each historic and gift context.Leading companies reviewed in the Zika Vaccines Market report are: Bharat Biotech, Inovio Pharmaceuticals, Cerus Corporation, Sanofi, NewLink Genetics, Immunovaccine, GlaxoSmithKlineIn market segmentation by types, the Zika Vaccines Market report covers: Therapeutic Vaccines, Preventive VaccinesIn market segmentation by applications, the Zika Vaccines Market report covers the following uses: Hospitals, Clinics, Ambulatory Surgery CentersEnquire Global Zika Vaccines Market report Discount: https://imrmarketreports.com/discount/24912IMR Market Reports provides discounts on each report.
we are able to provide Customization of the reports as per your necessities at cheap costs.
Global Zika Virus Vaccines Market by Type, Application, Regions and by Key Players, Forecast to 2026 documents an overview of the market trends, competitive structure, market shares of the competitors, market demands, market drivers, market restraints, and product analysis, and.
The report presents a detailed analysis of global Zika Virus Vaccines market size on regional and country-level, recent developments, segmentation market growth, strategic market growth analysis, opportunities analysis, and product launches.
Competitive landscape provides details by vendors, including company overview, global presence, company financials, market share, market potential, sales and revenue generated, price, consumption and production sales, SWOT analysis.DOWNLOAD SAMPLE REPORT: https://www.reportcrux.com/request-sample-report/Zika-Virus-Vaccines-by-Company-Profile-Deals-Type-Funding-Clinical-Trials-Insight-Regulatory-Landscape--Recent-DevelopmentMarketThe report highlights in-depth quantitative as well as qualitative insights, historical data, and market size projections till 2026.
It also gives a perspective on manufacturers, associations, specific organizations, industries, companies, and suppliers that work to expand their business worldwide.
Value chain analysis of the industry is explained in detail this providing a clear view of key mediators involved.
Key market players in the global Zika Virus Vaccines market, consist ofNHISanofiGSKakedaInovio PharmaceuticalsGeneOne Life Science IncPaxVaxGilead Sciences Inc.Intrexon Corp.NewLink Genetics Corp Request for Research Methodology: https://www.reportcrux.com/research-methodology/Zika-Virus-Vaccines-by-Company-Profile-Deals-Type-Funding-Clinical-Trials-Insight-Regulatory-Landscape--Recent-DevelopmentMarketRegional Analysis:Based on region, the market report is segmented into five main regions i.e.
Global Zika Virus Testing Market was valued at USD 131.9 million in 2016 and is estimated to grow significantly due to the growing demand for diagnostics from different parts of the world.
The disease prevention planning and funding therapeutic and is expected to boost the market growth in the coming years with a CAGR of 7.6%.Download Free Sample Report @ https://www.millioninsights.com/industry-reports/zika-virus-testing-market/request-sampleNo proper vaccination has been found against Zika Virus till date in spite of the extensive ongoing research; hence to relieve the symptoms care and comfort is the only way to deal with this situation.
The Zika Virus RNA detection test and the positive serum test for Immunoglobulin M (IgM) are performed to check and ascertain the presence of Zika Virus in the body.The research and development activities have been increased by the leading market players due to the government initiatives for the emergence of enhanced tests for detecting Zika Virus.
Also, incorrect results from defective diagnostic techniques can affect the Zika Virus Testing Market.Currently, the Zika Virus detection is done in view of clinical manifestations.
On the basis of test type, the market is divided into serological tests and molecular diagnostic tests which is also called as nucleic acid amplification tests.
It is (RT-PCR) Reverse Transcriptase Polymerase Chain Reaction that detects the existence of the Zika virus in human serum.
Emirates has transported 3,842,000 doses of bivalent oral polio vaccine (bOPV) to Uganda to support ongoing routine immunisation services throughout the country.
810,500 doses of Pentavalent Vaccines also procured by UNICEF with funding from Gavi, the Vaccine Alliance, are expected to arrive at Entebbe on April 282020.The vaccines procured by UNICEF, with funding from the government of Uganda, arrived at Entebbe International Airport.
